Tag: Policy

At a panel in Boston, senior officials announced plans to include aging in the agency’s regulatory science agenda and discussed how therapies could move toward approval. Longevity has a partner The 2026 edition of the Aging Research and Drug Discovery Meeting (ARDD) kicked off yesterday. This is one of the biggest and longest-running longevity conferences,...

Worldwide healthcare faces an unsustainable situation. We spend trillions managing the late-stage effects of biological aging, yet routinely overlook the underlying causes that drive them. Driven by an aging society, the financial burdens of treating diabetes, dementia, and heart disease are pushing Social Security and Medicare towards increasing and potentially catastrophic budget deficits [1]. Treating...

Montana’s first experimental treatment review board has brought three longevity heavyweights into the state’s effort to expand access to experimental therapies. How much regulation is too much? Many people in the longevity field will tell you that regulation is holding it back. Sensible oversight of novel therapies is essential, but an overly cautious interpretation of...

In this follow-up interview, we speak with Gabriel Cian about how the 2060 ecosystem has evolved since last year’s Forum, what he learned from the first edition, and how he is thinking about investment, scientific credibility, health optimization, policy, and the future of longevity in Europe. Last year, we spoke about your path from software...

In a recently published perspective paper, the author argues that the UK's official health guidelines on physical activity and protein intake should be revised to recommend levels necessary to achieve optimal health, rather than the bare minimum currently recommended [1]. From bare minimum to optimizing for healthspan Current government guidelines on nutrition and physical activity...

The longevity field remains small and starved for resources, especially the subfield devoted to the fundamental biology of aging, despite near-universal agreement that solving aging requires understanding it first. With VCs looking for clinical successes and state funding drying up for many projects, some enthusiasts are turning to a nonprofit model. That path is anything...